北米とヨーロッパの女性の健康市場、治療（医薬品とデバイス）、適応症（がん、生殖健康、泌尿器疾患、甲状腺機能低下症、閉経後症候群、その他）、提供モード（処方薬と市販薬）、医薬品タイプ（ブランド薬とジェネリック薬）、ケアタイプ（一般的なヘルスケアとウェルネス、妊娠と看護ケア、骨盤と子宮のヘルスケア、その他）、エンドユーザー（病院とクリニック、婦人科センター、在宅ケア環境、研究機関、その他）、流通チャネル（直接入札、小売販売、オンライン販売、その他） - 2031年までの業界動向と予測。
北米とヨーロッパの女性の健康市場の分析と規模
女性の慢性的な衰弱状態の増加率や、健康に影響を与えるライフスタイルや環境要因の変化は、市場の需要を押し上げる要因の一部です。また、全体的な健康と幸福を改善するための政府の取り組みも、市場の成長をさらに推進しています。市場に影響を与えている主な制約は、特定の製品に関連する副作用です。不妊治療の認識と受容の高まりは、市場の成長の機会として機能しています。高い妊産婦死亡率と罹患率は、市場の成長に対する課題となっています。
北米とヨーロッパの女性の健康市場は 、2023年の91億2,000万米ドルから2031年には164億9,000万米ドルに達し、2024年から2031年の予測期間に8.0%のCAGRで成長すると予想されています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2024年から2031年 |
|
基準年 |
2023 |
|
歴史的な年 |
2022 (2016～2021年にカスタマイズ可能) |
|
定量単位 |
収益（10億米ドル） |
|
対象セグメント |
治療（医薬品および医療機器）、適応症（がん、生殖健康、泌尿器疾患、甲状腺機能低下症、閉経後症候群など）、提供方法（処方薬および市販薬）、医薬品タイプ（ブランド薬およびジェネリック薬）、ケアタイプ（一般ヘルスケアおよびウェルネス、妊娠および看護ケア、骨盤および子宮ヘルスケアなど）、エンドユーザー（病院および診療所、婦人科センター、在宅ケア施設、研究機関など）、流通チャネル（直接入札、小売販売、オンライン販売など） |
|
対象国 |
米国、カナダ、メキシコ、ドイツ、フランス、イタリア、スペイン、スイス、オランダ、ベルギー、ロシア、トルコ、英国、その他のヨーロッパ諸国 |
|
対象となる市場プレーヤー |
リリー、アボット、ルピン、GSK plc.、ノバルティスAG、アッヴィ、ノーベン・ファーマシューティカルズ、バーティカル・ファーマシューティカルズ、ヴェル、ファイザーなど |
市場の定義
「女性の健康」として知られる医療およびヘルスケア サービスの分野は、人生のあらゆる段階で女性に影響を与える特定の生物学的、生理学的、および心理学的要件と問題に取り組んでいます。この分野は、女性特有の健康促進、婦人科ケア、生殖健康、および性的な健康に関連するさまざまなトピックをカバーしています。また、月経、避妊、妊娠、出産、更年期、および骨粗鬆症、子宮内膜症、乳がん、および卵巣がんなどの疾患に関連する性別特有の健康問題も、女性の健康でカバーされています。女性の健康では、ヘルスケアの結果、アクセス、および品質における男女格差を埋めることを目的とした検査、予防ケア、および介入にも重点が置かれています。
北米とヨーロッパの女性の健康市場の動向
このセクションでは、市場の推進要因、機会、課題、制約について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 女性における慢性的な衰弱性疾患の増加率
人口の高齢化は、北米とヨーロッパの女性における慢性疾患の発生率上昇の大きな要因です。女性は男性よりも、糖尿病、骨粗鬆症、心血管疾患、一部のがんなどの加齢に伴う病気にかかる可能性が高くなります。女性特有の病状の増加により、早期発見、効率的な治療、良好な結果を目指す新しい診断技術、治療アプローチ、予防策の需要が高まっています。医療提供者、製薬会社、医療機器メーカーは、変化する女性の需要をよりよく満たすために、研究開発への投資を増やすことでこのニーズに対応しています。これは、製品の提供範囲を広げ、医療提供モデルを改善することで実現します。
北米とヨーロッパで慢性疾患が女性の健康に与える影響を軽減するには、健康の社会的決定要因に対処し、医療サービスへのアクセスを改善し、健康的な行動を促進する公衆衛生対策が必要です。医療機関、立法者、研究者、コミュニティは、世界中の女性に影響を与え続けている骨粗鬆症、子宮内膜症、乳がん、卵巣がんなどの疾患に対処するために協力する必要があります。したがって、女性の間で慢性的な衰弱性疾患の割合が上昇していることが、市場の成長の主な原動力となっています。
- 研究開発活動の結果として開発される革新的な技術
医療技術の革命的な発展により、女性のヘルスケアの分野は変化しており、さまざまな疾患の診断、治療、管理に革新的なソリューションが提供されています。これらの発展は、標的薬、低侵襲手術法、精密医療、再生医療戦略など、幅広い技術を網羅しています。
専門的な医療サービスに対する需要、医療提供者、学者、技術開発者間の連携、インフラと労働力開発への投資はすべて、これらの新しい治療法の受け入れによって促進されています。
モバイル ヘルス アプリ、遠隔医療、リモート モニタリングなどのデジタル ヘルス テクノロジーの導入により、医療へのアクセスが向上し、女性が医療業界で積極的な役割を果たすことができるようになりました。その結果、女性の健康市場は北米とヨーロッパ全体で急速に拡大し、革新が進んでいます。新しいテクノロジーにより、患者の治療結果、治療の質、医療の提供全体が進歩しています。したがって、研究開発活動の結果として開発されている革新的なテクノロジーが、市場の成長を促進しています。
機会
- メンタルヘルスへの認識の高まり
うつ病、不安障害、産後うつ病、摂食障害などのメンタルヘルスの問題は、生物学的、心理学的、社会的要因の組み合わせにより、女性に不釣り合いなほど大きな影響を与えます。メンタルヘルスの問題に対する意識の高まりにより、革新的な治療法、デジタルメンタルヘルスツール、女性特有のニーズに合わせたサポートサービスの需要が高まっています。
したがって、この需要に応えて、女性のメンタルヘルスを専門とする企業には、女性の精神的健康を改善し、メンタルヘルス障害に対処することを目的としたさまざまなソリューションを開発し、提供する機会があります。
デジタルメンタルヘルスツールや、女性特有のニーズに合わせたサポートサービスにより、市場の関係者は、多様なコミュニティの女性のメンタルヘルス成果の改善と生活の質の向上に貢献できます。これは、革新的な治療法の開発に投資することで実現します。北米とヨーロッパの女性の間でメンタルヘルスと幸福の重要性が認識されつつあることは、市場の成長にとって大きなチャンスとなります。
制約/課題
- 特定の製品に関連する副作用
近年、パーソナルケア用品、医療機器、医薬品など、女性の健康を目的としたさまざまな製品の有効性と安全性に関する懸念が浮上しています。消費者、医療従事者、規制機関は、ホルモン補充療法、避妊法、美容整形手術など、これらの製品の副作用を懸念しています。
薬物使用による女性の健康への悪影響は一般的であり、綿密な観察、インフォームドコンセント、個別の治療計画の重要性が強調されています。医療専門家は、患者の好み、年齢、病歴、併存疾患を考慮して、薬物療法の利点と欠点を慎重に比較検討する必要があります。したがって、特定の製品に関連する悪影響は、市場の成長を抑制すると予想されます。
- 環境曝露が生殖の健康に及ぼす影響
北米とヨーロッパでは、工業化、都市化、農業、製造業、消費財における化学物質の広範な使用により、環境曝露が女性の生殖健康に重大な課題をもたらしています。プラスチックやパーソナルケア製品に含まれる BPA、フタル酸エステル、農薬などの内分泌かく乱化学物質 (EDC) への曝露は、不妊、月経不順、ホルモンの不均衡につながる可能性があります。産業排出物や自動車排気ガスによる大気汚染は、早産や低出生体重など妊娠の悪影響の一因となります。女性の健康市場の利害関係者は、さまざまなコミュニティの女性の生殖健康のリスクを軽減し、保護することができます。これは、意識を高め、予防措置を実施し、環境汚染を削減する政策を提唱することで実現できます。生殖健康に影響を与える環境曝露は、市場の成長にとって多面的な課題を表しています。
最近の動向
- 2023年11月、ルピンはMENA地域およびさまざまな世界市場で存在感を示す大手製薬メーカーであるアンマン・ファーマシューティカルズ・インダストリーズ（アンマン・ファーマ）と独占的パートナーシップを締結しました。この提携には、ルセンティスのバイオシミラーであるラニビズマブの販売権と商品化権が含まれます。この戦略的パートナーシップにより、ルピンは新しい地域に参入し、市場での存在感を拡大し、最終的に製薬業界における同社の地位を強化することができます。
- 2023年7月、GSK plcは、米国食品医薬品局（FDA）が、FDA承認の検査でマイクロサテライト不安定性高（MSI-H）またはミスマッチ修復欠損（dMMR）と判定された原発性進行性または再発性子宮内膜がんの成人患者の治療薬として、ジェンペルリ（ドスタルリマブ）を単剤として承認したと発表しました。これにより、同社は製品ラインナップを拡大することができました。
- 2022年8月、Myovant SciencesとPfizer Inc.は、米国食品医薬品局（FDA）が閉経前女性の子宮内膜症に伴う中等度から重度の痛みの管理のための1日1回1錠の治療法としてMYFEMBREE（レルゴリクス40mg、エストラジオール1mg、ノルエチンドロン酢酸塩0.5mg）を承認したと発表した。治療期間は最長24か月続く可能性がある。これにより、同社は製品ラインを拡大することができた。
- 2020年11月、専門医薬品会社であるAvion Pharmaceuticals（Alora Pharmaceuticals LLCの子会社）は、Aspen Pharma USA Inc.およびAspen Global Incorporatedと独占的ライセンスおよび商業化契約を締結しました。この契約により、Avionは、9種類の結合型エストロゲンの唯一の植物由来ブレンドであるCenestin（合成結合型エストロゲン、A）タブレットを再発売する独占権を取得します。
- 2020年6月、アッヴィ社はニューロクラインバイオサイエンス社と共同で、米国食品医薬品局（FDA）がORIAHNN（エラゴリクス、エストラジオール、ノルエチンドロンアセテートカプセル、エラゴリクスカプセル）を承認し、最大24か月の治療期間を認めたことを発表しました。ORIAHNNは、閉経前女性の子宮筋腫に関連する月経過多に対処するための、FDA承認の初の非外科的経口治療オプションです。この承認により、同社の女性向け健康医薬品のポートフォリオが拡大し、ニューロクラインバイオサイエンス社がこの分野の主要プレーヤーとしての地位を確立します。
北米とヨーロッパの女性の健康市場の範囲
北米とヨーロッパの女性の健康市場は、治療、適応症、提供方法、薬剤の種類、ケアの種類、エンドユーザー、流通チャネルに基づいて、7 つの主要なセグメントに分類されています。これらのセグメントの成長は、業界の主要な成長セグメントの分析に役立ち、ユーザーに貴重な市場の概要と市場の洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
処理
- 薬物
- デバイス
治療に基づいて、北米とヨーロッパの女性の健康市場は医薬品とデバイスに分類されます。
表示
- 癌
- 生殖に関する健康
- 泌尿器疾患
- 甲状腺機能低下症
- 閉経後症候群
- その他
適応症に基づいて、北米とヨーロッパの女性の健康市場は、がん、生殖健康、泌尿器疾患、甲状腺機能低下症、閉経後症候群、その他に分類されます。
配送モード
- 処方箋
- 店頭
提供方法に基づいて、北米とヨーロッパの女性の健康市場は処方薬と市販薬に分類されます。
薬剤の種類
- ブランド
- ジェネリック
医薬品の種類に基づいて、北米とヨーロッパの女性の健康市場はブランド薬とジェネリック薬に分類されます。
ケアの種類
- 一般的なヘルスケアと健康
- 妊娠と看護
- 骨盤と子宮のヘルスケア
- その他
ケアの種類に基づいて、北米とヨーロッパの女性の健康市場は、一般的なヘルスケアとウェルネス、妊娠と看護ケア、骨盤と子宮のヘルスケア、その他に分類されます。
エンドユーザー
- 病院と診療所
- 婦人科センター
- ホームケア設定
- 研究機関
- その他
北米とヨーロッパの女性の健康市場は、エンドユーザーに基づいて、病院や診療所、婦人科センター、在宅ケア施設、研究機関などに分類されます。
流通チャネル
- 直接入札
- 小売販売
- オンライン販売
- その他
流通チャネルに基づいて、北米とヨーロッパの女性の健康市場は、直接入札、小売販売、オンライン販売、その他に分類されます。
北米とヨーロッパの女性の健康市場の地域分析/洞察
北米とヨーロッパの女性の健康市場は、治療、適応症、提供方法、薬剤の種類、ケアの種類、エンドユーザー、流通チャネルに基づいて、7 つの主要なセグメントに分類されています。
市場対象となる国は、米国、カナダ、メキシコ、ドイツ、フランス、イタリア、スペイン、スイス、オランダ、ベルギー、ロシア、トルコ、英国、およびその他のヨーロッパ諸国です。
北米は、この地域での研究開発活動の結果として革新的な技術が開発されているため、北米とヨーロッパの女性の健康市場を支配すると予想されています。米国は、女性の健康部門のための高度な医療インフラと技術革新の存在により、北米の女性の健康市場を支配すると予想されています。ドイツは、広範な流通ネットワークにより国際市場で強力な存在感を示しているため、ヨーロッパの女性の健康市場を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の動向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。データポイントの下流および上流のバリューチェーン分析、技術動向、ポーターの 5 つの力の分析、およびケーススタディは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、地域ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税の影響、貿易ルートも考慮されます。
北米とヨーロッパの女性の健康市場シェア分析
北米とヨーロッパの女性の健康市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。
北米およびヨーロッパの女性の健康市場で活動している主要な市場プレーヤーとしては、Lilly、Abbott、Lupin、GSK plc.、Novartis AG、AbbVie Inc.、Noven Pharmaceuticals, Inc.、Vertical Pharmaceuticals, LLC、Veru Inc.、Pfizer Inc. などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRY INSIGHTS
4.3.1 DRUG TREATMENT RATE IN MATURED MARKETS
4.3.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.3.3 PATIENT FLOW DIAGRAMS
4.3.4 KEY PRICING STRATEGIES
4.3.5 KEY ENROLLMENT STRATEGIES
4.4 PIPELINE ANALYSIS
4.5 PATENT DATA ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN
5.1.2 INNOVATIVE TECHNOLOGIES BEING DEVELOPED AS AN AFTERMATH OF R&D ACTIVITIES
5.1.3 GOVERNMENT INITIATIVES TO IMPROVE OVERALL HEALTH AND WELLBEING
5.1.4 CHANGING LIFESTYLES AND ENVIRONMENTAL FACTORS IMPACTING HEALTH
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH CERTAIN PRODUCTS
5.2.2 STRICT REGULATIONS IMPOSED BY THE REGULATORY AGENCIES
5.3 OPPORTUNITIES
5.3.1 INCREASING RECOGNITION FOR MENTAL HEALTH
5.3.2 GROWING AWARENESS AND ACCEPTANCE OF FERTILITY TREATMENTS
5.3.3 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.4 CHALLENGES
5.4.1 ENVIRONMENTAL EXPOSURE IMPACTING REPRODUCTIVE HEALTH
5.4.2 HIGH MATERNAL MORTALITY AND MORBIDITY
6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 DEVICE
7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CANCER
7.3 REPRODUCTIVE HEALTH
7.4 UROLOGICAL DISORDERS
7.5 HYPOTHYROIDISM
7.6 POST-MENOPAUSAL SYNDROME
7.7 OTHERS
8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE
8.1 OVERVIEW
8.2 GENERAL HEALTHCARE & WELLNESS
8.3 PREGNANCY & NURSING CARE
8.4 PELVIC & UTERINE HEALTHCARE
8.5 OTHERS
9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DELIVERY MODE
10.1 OVERVIEW
10.2 PRESCRIPTION
10.3 OVER THE COUNTER
11 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS AND CLINICS
11.3 GYNECOLOGY CENTERS
11.4 HOMECARE SETTING
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 U.K.
13.2.4 ITALY
13.2.5 RUSSIA
13.2.6 SPAIN
13.2.7 TURKEY
13.2.8 NETHERLANDS
13.2.9 SWITZERLAND
13.2.10 BELGIUM
13.2.11 REST OF EUROPE
14 NORTH AMERICA AND EUROPE WOMEN HEALTH MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.2 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 ABBVIE INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 GSK PLC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 LILLY
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 LUPIN
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NOVARTIS AG
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 NOVEN PHARMACEUTICALS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 PFIZER INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 VERTICAL PHARMACEUTICALS, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 VERU INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DEVICES
TABLE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DRUGS
TABLE 3 PATENT DATA (1/4)
TABLE 4 PATENT DATA (2/4)
TABLE 5 PATENT DATA (3/4)
TABLE 6 PATENT DATA (4/4)
TABLE 7 NORTH AMERICA WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 8 EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 EUROPE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 EUROPE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION
TABLE 18 EUROPE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 EUROPE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 EUROPE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 EUROPE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 EUROPE INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 EUROPE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 EUROPE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 EUROPE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 EUROPE CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 50 EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 EUROPE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 EUROPE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 58 EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 60 EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 EUROPE WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 66 U.S. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 67 U.S. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 U.S. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.S. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.S. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.S. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.S. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.S. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.S. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.S. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 U.S. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 U.S. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.S. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.S. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 U.S. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 88 U.S. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 90 U.S. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 U.S. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 94 U.S. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 95 CANADA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 96 CANADA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 CANADA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 CANADA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 CANADA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 CANADA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 CANADA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 CANADA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 CANADA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 CANADA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 CANADA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 CANADA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 CANADA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 CANADA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 CANADA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 112 CANADA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 CANADA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 117 CANADA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 CANADA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 CANADA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 123 CANADA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 124 MEXICO WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 MEXICO HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 MEXICO ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 MEXICO PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 MEXICO COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 MEXICO GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 MEXICO GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 MEXICO LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MEXICO NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MEXICO INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 MEXICO AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MEXICO DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 MEXICO INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 MEXICO WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 141 MEXICO CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MEXICO UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 MEXICO PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 MEXICO WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EUROPE WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 154 GERMANY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 GERMANY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 GERMANY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 GERMANY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 GERMANY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 GERMANY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 GERMANY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 GERMANY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 GERMANY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 GERMANY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 GERMANY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 GERMANY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 GERMANY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 GERMANY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 170 GERMANY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 171 GERMANY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 GERMANY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 GERMANY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 GERMANY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 175 GERMANY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 176 GERMANY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 177 GERMANY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 178 GERMANY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 GERMANY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 GERMANY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 GERMANY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 FRANCE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 FRANCE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 FRANCE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 FRANCE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 FRANCE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 FRANCE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 FRANCE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 FRANCE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 FRANCE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 193 FRANCE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 FRANCE INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 FRANCE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 FRANCE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 FRANCE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 FRANCE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 200 FRANCE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 FRANCE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 FRANCE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 FRANCE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 FRANCE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 205 FRANCE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 206 FRANCE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 207 FRANCE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 FRANCE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 FRANCE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 FRANCE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 FRANCE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 U.K. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 U.K. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 U.K. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 215 U.K. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 U.K. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 U.K. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 U.K. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 U.K. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 U.K. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 U.K. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 U.K. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 U.K. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 225 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 U.K. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 227 U.K. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 U.K. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 229 U.K. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 U.K. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 U.K. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 232 U.K. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 U.K. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 234 U.K. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 235 U.K. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 236 U.K. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 U.K. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 U.K. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 U.K. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 240 U.K. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 241 ITALY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 ITALY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 ITALY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 ITALY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 245 ITALY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 ITALY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 ITALY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 ITALY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 ITALY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 ITALY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 252 ITALY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 ITALY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ITALY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ITALY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 ITALY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 258 ITALY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 ITALY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 ITALY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 ITALY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 ITALY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 263 ITALY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 264 ITALY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 265 ITALY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ITALY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ITALY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ITALY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ITALY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 RUSSIA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 271 RUSSIA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 RUSSIA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 RUSSIA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 RUSSIA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 RUSSIA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 RUSSIA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 RUSSIA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 RUSSIA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 RUSSIA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 RUSSIA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 RUSSIA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 RUSSIA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 286 RUSSIA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 287 RUSSIA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 RUSSIA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 RUSSIA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 RUSSIA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 RUSSIA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 292 RUSSIA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 293 RUSSIA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 294 RUSSIA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 RUSSIA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 296 RUSSIA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 RUSSIA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 298 RUSSIA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 299 SPAIN WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 300 SPAIN DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 SPAIN HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 302 SPAIN ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 SPAIN PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 304 SPAIN COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 SPAIN GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 SPAIN GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 307 SPAIN LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 SPAIN NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 310 SPAIN INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 311 SPAIN AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 SPAIN DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 SPAIN INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 315 SPAIN WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 316 SPAIN CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 SPAIN REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 SPAIN UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 319 SPAIN OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 320 SPAIN WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 321 SPAIN WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 322 SPAIN WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 323 SPAIN GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 324 SPAIN PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 SPAIN PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 SPAIN WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 327 SPAIN WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 328 TURKEY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 329 TURKEY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 330 TURKEY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 331 TURKEY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 332 TURKEY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 333 TURKEY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 TURKEY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 TURKEY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 336 TURKEY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 337 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 338 TURKEY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 339 TURKEY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 340 TURKEY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 341 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 TURKEY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 TURKEY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 344 TURKEY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 345 TURKEY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 TURKEY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 347 TURKEY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 348 TURKEY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 349 TURKEY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 350 TURKEY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 351 TURKEY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 352 TURKEY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 353 TURKEY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 354 TURKEY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 355 TURKEY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 TURKEY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 NETHERLANDS WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 358 NETHERLANDS DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 359 NETHERLANDS HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 NETHERLANDS ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 NETHERLANDS PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 362 NETHERLANDS COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 363 NETHERLANDS GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 365 NETHERLANDS LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 366 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 367 NETHERLANDS NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 368 NETHERLANDS INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 NETHERLANDS AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 371 NETHERLANDS DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 372 NETHERLANDS INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 373 NETHERLANDS WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 374 NETHERLANDS CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 375 NETHERLANDS REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 376 NETHERLANDS UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 NETHERLANDS OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 NETHERLANDS WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 379 NETHERLANDS WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 380 NETHERLANDS WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 381 NETHERLANDS GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 382 NETHERLANDS PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 383 NETHERLANDS PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 384 NETHERLANDS WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 385 NETHERLANDS WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 386 SWITZERLAND WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 387 SWITZERLAND DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 388 SWITZERLAND HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 389 SWITZERLAND ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 390 SWITZERLAND PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 391 SWITZERLAND COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 392 SWITZERLAND GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 393 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 SWITZERLAND LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 396 SWITZERLAND NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 397 SWITZERLAND INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 SWITZERLAND AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 399 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 400 SWITZERLAND DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 401 SWITZERLAND INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 402 SWITZERLAND WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 403 SWITZERLAND CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 SWITZERLAND REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 405 SWITZERLAND UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 406 SWITZERLAND OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 407 SWITZERLAND WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 408 SWITZERLAND WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 409 SWITZERLAND WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 410 SWITZERLAND GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SWITZERLAND PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SWITZERLAND PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 413 SWITZERLAND WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 414 SWITZERLAND WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 415 BELGIUM WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 416 BELGIUM DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 417 BELGIUM HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 418 BELGIUM ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 419 BELGIUM PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 BELGIUM COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 BELGIUM GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 422 BELGIUM GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 423 BELGIUM LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 424 BELGIUM GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 425 BELGIUM NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 426 BELGIUM INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 427 BELGIUM AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 BELGIUM DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 430 BELGIUM INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 431 BELGIUM WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 432 BELGIUM CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 433 BELGIUM REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 434 BELGIUM UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 435 BELGIUM OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 436 BELGIUM WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 437 BELGIUM WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 438 BELGIUM WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 439 BELGIUM GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 440 BELGIUM PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 441 BELGIUM PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 442 BELGIUM WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 444 REST OF EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET
FIGURE 14 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 15 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 16 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 17 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 19 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 21 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 23 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 24 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 27 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 29 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 31 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 32 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 34 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 35 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 38 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 39 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 40 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 42 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 43 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 45 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 47 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 48 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 49 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 50 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 51 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 53 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 54 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 55 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 56 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 57 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 59 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 60 EUROPE WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 61 EUROPE WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 63 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 64 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 65 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 66 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 67 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 68 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 69 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 NORTH AMERICA WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 71 EUROPE WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 72 NORTH AMERICA WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
FIGURE 73 EUROPE WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
